|Videos|May 2, 2023
Interview with Jubilant’s President Chris Preti
Author(s)Jubilant
Key Learning Objectives:
- Progress on previously announced $285 million expansion plan will double capacity for sterile injectables fill/finish at Jubilant HollisterStier’s Spokane, Wash. Facility
- Strengthen’s Jubilant HollisterStier’s position in addressing contract manufacturing needs of major producers throughout North America
- Jubilant HollisterStier is a leading contract manufacturer of sterile injectables, ophthalmics, optics, sterile and non-sterile topicals and liquids
Related Content
Trending on Pharmaceutical Technology
1
The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma
2
The FDA Moves to Modernize Drug Manufacturing Registration
3
PharmTech Weekly Roundup–July 10, 2026
4
What the Ocrelizumab Deal Does for the Multiple Sclerosis Biosimilar Pipeline
5